Peer review reports
From: Combined treatment of Nimotuzumab and rapamycin is effective against temozolomide-resistant human gliomas regardless of the EGFR mutation status
Original Submission |
12 Dec 2014 |
Submitted |
Original manuscript
|
|
Author responded |
Author comments
|
|
Reviewed |
Reviewer Report
|
Resubmission - Version 2 |
|
Submitted |
Manuscript version 2
|
Publishing |
13 Mar 2015 |
Editorially accepted |
|
11 Apr 2015 |
Article published |
10.1186/s12885-015-1191-3
|
Learn about peer review